Your browser doesn't support javascript.
loading
Personality assessment with Temperament and Character Inventory in Parkinson's disease.
Boussac, Mathilde; Arbus, Christophe; Colin, Olivier; Laurencin, Chloé; Eusebio, Alexandre; Hainque, Elodie; Corvol, Jean Christophe; Versace, Nathalie; Rascol, Olivier; Rousseau, Vanessa; Harroch, Estelle; Ory-Magne, Fabienne; Fabbri, Margherita; Moreau, Caroline; Rolland, Anne-Sophie; Jarraya, Béchir; Maltête, David; Drapier, Sophie; Marques, Ana-Raquel; Auzou, Nicolas; Wirth, Thomas; Meyer, Mylène; Giordana, Bruno; Tir, Mélissa; Rouaud, Tiphaine; Devos, David; Brefel-Courbon, Christine.
Afiliação
  • Boussac M; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France. Electronic address: mathilde.boussac@inserm.fr.
  • Arbus C; Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
  • Colin O; Service de neurologie, Centre Hospitalier de Brive-la-Gaillarde, France; Centre Expert Parkinson, CHU de Limoges, France.
  • Laurencin C; Service de neurologie C - Hôpital Neurologique - 59 boulevard Pinel 69003 Lyon - Hospices Civils de Lyon, France.
  • Eusebio A; Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
  • Hainque E; Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; et Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau, F-75013, Paris, France.
  • Corvol JC; Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; et Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau, F-75013, Paris, France.
  • Versace N; Department of Neurology, Hôpital Fondation Rothschild, Paris, France.
  • Rascol O; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-
  • Rousseau V; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.
  • Harroch E; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.
  • Ory-Magne F; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-
  • Fabbri M; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-
  • Moreau C; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.
  • Rolland AS; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.
  • Jarraya B; Service de Neurologie, Unité des Mouvements Anormaux, Foch Hospital, Suresnes, France; Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, Saclay, France.
  • Maltête D; Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.
  • Drapier S; Service de neurologie, CHU Rennes, CIC INSERM, 1414, Rennes, France.
  • Marques AR; Université Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand University Hospital, Neurology department, France.
  • Auzou N; Institut des Maladies neurodégénératives, Pôle des neurosciences cliniques, CHU Bordeaux, France; Service de neurophysiologie clinique de l'enfant et de l'adulte, Pôle des neurosciences cliniques, CHU Bordeaux, France.
  • Wirth T; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM-U964/CNRSUMR7104/Université de Strasbourg, Illkirch-Graffenstaden, France; Fédération de Médecine Translationnelle de Strasbourg, Université de Str
  • Meyer M; Neurology Department of the University Hospital of Nancy, CHRU de Nancy, Nancy, France.
  • Giordana B; CHU Nice, Department of Psychiatry and Psychotherapy, Nice, France.
  • Tir M; Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens
  • Rouaud T; Department of Neurology, Expert Centre for Parkinson's Disease, University Hospital of Nantes, Nantes, France.
  • Devos D; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.
  • Brefel-Courbon C; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-
Parkinsonism Relat Disord ; 103: 34-41, 2022 10.
Article em En | MEDLINE | ID: mdl-36030666
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Ansiolíticos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Parkinsonism Relat Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Ansiolíticos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Parkinsonism Relat Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article